Free Trial

BI Asset Management Fondsmaeglerselskab A S Purchases 33,394 Shares of DaVita Inc. $DVA

DaVita logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • BI Asset Management Fondsmaeglerselskab A S increased its DaVita stake by 63.5% in the fourth quarter, buying 33,394 shares to bring its total holding to 86,000 shares worth about $9.77 million.
  • Several other institutional investors also boosted their positions, and 90.12% of DaVita shares are now owned by institutions, indicating strong institutional interest in the stock.
  • Analysts have recently turned more positive on DaVita, with multiple upgrades and higher price targets; the consensus rating is currently Hold with an average price target of $199.17.
  • Interested in DaVita? Here are five stocks we like better.

BI Asset Management Fondsmaeglerselskab A S lifted its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 63.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 86,000 shares of the company's stock after purchasing an additional 33,394 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S owned about 0.12% of DaVita worth $9,770,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in DVA. Norges Bank bought a new stake in shares of DaVita during the fourth quarter valued at approximately $49,164,000. Arrowstreet Capital Limited Partnership boosted its position in shares of DaVita by 109.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company's stock valued at $73,585,000 after purchasing an additional 289,725 shares in the last quarter. Man Group plc raised its stake in DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company's stock valued at $40,713,000 after buying an additional 269,081 shares during the last quarter. Neuberger Berman Group LLC raised its stake in DaVita by 138.5% during the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company's stock valued at $61,502,000 after buying an additional 269,015 shares during the last quarter. Finally, Voloridge Investment Management LLC raised its stake in DaVita by 2,905.7% during the third quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company's stock valued at $30,324,000 after buying an additional 220,628 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DVA has been the subject of a number of recent research reports. Truist Financial lifted their price objective on DaVita from $158.00 to $205.00 and gave the company a "hold" rating in a research note on Friday, May 8th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, February 21st. Zacks Research upgraded DaVita from a "hold" rating to a "strong-buy" rating in a research note on Thursday, May 7th. TD Cowen lifted their price objective on DaVita from $144.00 to $201.00 and gave the company a "hold" rating in a research note on Monday, May 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded DaVita from a "hold" rating to a "buy" rating and lifted their price objective for the company from $126.00 to $220.00 in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $199.17.

Get Our Latest Stock Analysis on DVA

DaVita Price Performance

DVA stock opened at $192.28 on Friday. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $202.69. The business has a fifty day moving average price of $171.47 and a 200-day moving average price of $143.18. The stock has a market capitalization of $12.34 billion, a P/E ratio of 17.84, a P/E/G ratio of 0.63 and a beta of 0.91.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion during the quarter, compared to analysts' expectations of $3.36 billion. During the same quarter in the previous year, the business earned $2.00 earnings per share. The company's revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts anticipate that DaVita Inc. will post 15.07 earnings per share for the current year.

Insider Buying and Selling at DaVita

In other news, CFO Joel Ackerman sold 51,471 shares of the business's stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is owned by corporate insiders.

DaVita Company Profile

(Free Report)

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Featured Articles

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DaVita Right Now?

Before you consider DaVita, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.

While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines